NYSE:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis $0.60 +0.04 (+7.14%) As of 06/4/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About NovaBay Pharmaceuticals Stock (NYSE:NBY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NBY alerts:Sign Up Key Stats Today's Range$0.56▼$0.6050-Day Range$0.47▼$0.6052-Week Range$0.36▼$3.15Volume160,938 shsAverage Volume141,622 shsMarket Capitalization$3.47 millionP/E RatioN/ADividend YieldN/APrice Target$0.85Consensus RatingBuy Company OverviewNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Read More… NovaBay Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreNBY MarketRank™: NovaBay Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNovaBay Pharmaceuticals has received no research coverage in the past 90 days.Read more about NovaBay Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($3.26) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovaBay Pharmaceuticals has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NBY. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovaBay Pharmaceuticals does not currently pay a dividend.Dividend GrowthNovaBay Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NBY. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for NBY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, NovaBay Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $98,137.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.10% of the stock of NovaBay Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 23.25% of the stock of NovaBay Pharmaceuticals is held by institutions.Read more about NovaBay Pharmaceuticals' insider trading history. Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NBY Stock News HeadlinesNovaBay Pharmaceuticals Inc. Stock Grades | NBY | Barron'sMay 26, 2025 | barrons.comNovaBay Pharmaceuticals approves liquidation planApril 24, 2025 | uk.investing.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.June 5, 2025 | Crypto 101 Media (Ad)NovaBay Pharmaceuticals Delays Yearly Report FilingApril 1, 2025 | tipranks.comNovaBay Pharmaceuticals to Hold Special Meeting of StockholdersMarch 7, 2025 | businesswire.comNovaBay fails to gain shareholder approval for dissolutionFebruary 5, 2025 | msn.comNovaBay Pharmaceuticals Inc NBYFebruary 2, 2025 | morningstar.comNovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of StockholdersDecember 19, 2024 | businesswire.comSee More Headlines NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed this year? NovaBay Pharmaceuticals' stock was trading at $0.6010 on January 1st, 2025. Since then, NBY stock has decreased by 0.7% and is now trading at $0.5970. View the best growth stocks for 2025 here. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSE:NBY) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.32. The company had revenue of $2.44 million for the quarter, compared to analysts' expectations of $2.50 million. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 7,293.78% and a negative net margin of 102.72%. When did NovaBay Pharmaceuticals' stock split? NovaBay Pharmaceuticals's stock reverse split on Friday, May 31st 2024. The 1-35 reverse split was announced on Friday, May 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Adverum Biotechnologies (ADVM), American Resources (AREC), Clearside Biomedical (CLSD), Hello Group (MOMO), Palatin Technologies (PTN), Xeris Biopharma (XERS) and Algonquin Power & Utilities (AQN). Company Calendar Last Earnings11/07/2024Today6/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NBY CIK1389545 Webnovabay.com Phone510-899-8800Fax510-474-1577Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$0.85 High Stock Price Target$0.85 Low Stock Price Target$0.85 Potential Upside/Downside+42.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($53.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.64 million Net Margins-102.72% Pretax Margin-99.12% Return on Equity-7,293.78% Return on Assets-158.41% Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio0.91 Sales & Book Value Annual Sales$9.78 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book Value$4.25 per share Price / Book0.14Miscellaneous Outstanding Shares5,816,000Free Float4,881,000Market Cap$3.47 million OptionableNot Optionable Beta0.42 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NYSE:NBY) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.